Tafamidis meglumine

Drug Profile

Tafamidis meglumine

Alternative Names: Fx-1006A; FX1006A; PF-06291826; PF-6291826; Tafamidis; Vyndaqel

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator FoldRx Pharmaceuticals
  • Developer FoldRx Pharmaceuticals; Pfizer
  • Class Benzoxazoles; Carboxylic acids; Chlorobenzenes; Small molecules
  • Mechanism of Action Amyloid inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyloid polyneuropathy; Cardiomyopathies
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Amyloid polyneuropathy
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Amyloid polyneuropathy
  • Phase III Cardiomyopathies

Most Recent Events

  • 08 Aug 2016 Post-hoc adverse events and efficacy data from three phase III trials in Amyloid polyneuropathy released by Pfizer
  • 05 Aug 2016 Pfizer completes a phase I bioavailability trial in Healthy volunteers in Belgium (PO) (NCT02697864)
  • 01 Jul 2016 Pfizer completes a phase-I bioavailability trial in Healthy volunteers in USA (PO) (NCT02746926)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top